Literature DB >> 9125387

Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study.

P Cortelli1, P Montagna, G Pierangeli, R Lodi, P Barboni, R Liguori, V Carelli, S Iotti, P Zaniol, E Lugaresi, B Barbiroli.   

Abstract

We used phosphorus magnetic resonance spectroscopy (31P-MRS) to study in vivo brain and muscle bioenergetics in a male patient with Leber's hereditary optic neuropathy (LHON) and mtDNA mutation at 11,778 bp who developed spastic paraparesis with white matter lesions on brain MR imaging. The study was performed before and during treatment with idebenone (135 mg t.i.d.) and after withdrawal. Clinical amelioration and worsening were associated with parallel changes in brain and skeletal muscle bioenergetics following the administration or withdrawal of idebenone. Reversal of paraparesis by idebenone was paralleled by normalization of 31P-MRS, serum lactate and central motor conduction. Extra-ocular neurological dysfunction in LHON may be amenable to treatment by appropriate quinones.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125387     DOI: 10.1016/s0022-510x(96)00311-5

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  22 in total

1.  Spastic paraparesis as a manifestation of Leber's disease.

Authors:  Frédéric Clarençon; Emmanuel Touzé; Anne Leroy-Willig; Hélène Turmel; Olivier Naggara; Stéphane Pavy; Antoine Brézin; Jean-Louis Mas
Journal:  J Neurol       Date:  2005-11-23       Impact factor: 4.849

2.  Treatment of Leber hereditary optic neuropathy.

Authors:  Nancy J Newman
Journal:  Brain       Date:  2011-08-22       Impact factor: 13.501

Review 3.  Novel therapeutic approaches for Leber's hereditary optic neuropathy.

Authors:  Shilpa Iyer
Journal:  Discov Med       Date:  2013-03       Impact factor: 2.970

Review 4.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

Review 5.  Maintenance treatment of glutaryl-CoA dehydrogenase deficiency.

Authors:  C Mühlhausen; G F Hoffmann; K A Strauss; S Kölker; J G Okun; C R Greenberg; E R Naughten; K Ullrich
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 6.  Therapies in inborn errors of oxidative metabolism.

Authors:  Manuel Schiff; Paule Bénit; Howard T Jacobs; Jerry Vockley; Pierre Rustin
Journal:  Trends Endocrinol Metab       Date:  2012-05-25       Impact factor: 12.015

7.  Leber's Hereditary Optic Neuropathy.

Authors:  Alfredo A Sadun; Chiara La Morgia; Valerio Carelli
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

Review 8.  Treatment of hereditary optic neuropathies.

Authors:  Nancy J Newman
Journal:  Nat Rev Neurol       Date:  2012-09-04       Impact factor: 42.937

9.  Structural impairment patterns in peripapillary retinal fiber layer and retinal ganglion cell layer in mitochondrial optic neuropathies.

Authors:  Da Teng; Chun-Xia Peng; Hai-Yan Qian; Li Li; Wei Wang; Jun-Qing Wang; Bing Chen; Huan-Fen Zhou; Shi-Hui Wei
Journal:  Int J Ophthalmol       Date:  2018-10-18       Impact factor: 1.779

10.  Idebenone: A Review in Leber's Hereditary Optic Neuropathy.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.